ADARx Pharmaceuticals, Inc.

NASDAQ:ADRX

Biotechnology

Healthcare
$13.82 +0.73%

+$0.13 today

Market cap
$1.53B
Beta
0.00
52W Low $16.64High $23.21

Volume 0.70M

Average 1.06M

Big Five Numbers

ADARx Pharmaceuticals, Inc. growth analysis

Start with the long-run numbers that show whether ADRX compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/AN/A
Equity
N/AN/AN/AN/A
Cash
N/AN/AN/AN/A
ROIC
N/AN/AN/AN/A

Analysis

Analysis will appear once enough financial history is available for this company.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where ADRX earns its revenue, as reported in company filings

This company does not report revenue segments.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

No cash flow data available.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for ADRX.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for ADRX.

Sign in free

Competitor growth

How does ADARx Pharmaceuticals, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Stoke Therapeutics, Inc.

STOK

$1.75B——+145.9%
+27.1% (5yr)5 analysts

Silence Therapeutics plc

SLN

$936.65M—-36.7%-68.4%
+213.7% (5yr)3 analysts

MeiraGTx Holdings plc

MGTX

$881.67M—+39.2%+72.3%
+48.6% (5yr)2 analysts

Prime Medicine, Inc.

PRME

$774.48M—-2.3%—
+87.0% (5yr)5 analysts

Wave Life Sciences Ltd.

WVE

$617.33M+75.7%+16.3%+127.1%
+53.3% (5yr)9 analysts

Benitec Biopharma Inc.

BNTC

$315.40M———
—1 analysts

Arcturus Therapeutics Holdings Inc.

ARCT

$240.96M+27.0%+47.8%-31.1%
+37.7% (5yr)5 analysts

ProQR Therapeutics N.V.

PRQR

$198.98M+5.0%+71.5%+62.0%
+48.5% (5yr)2 analysts

Atrium Therapeutics, Inc.

RNA

$128.46M———
+0.0% (5yr)2 analysts

Questions

Growth questions

Common questions about ADRX's growth, answered from reported and forecast figures.